

# Karel Pacak

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4091175/karel-pacak-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

487  
papers

27,758  
citations

85  
h-index

150  
g-index

508  
ext. papers

32,417  
ext. citations

6.7  
avg, IF

7.02  
L-index

#	Paper	IF	Citations
487	New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	5
486	Somatic Mosaicism of EPAS1 Mutations in Pacak-Zhuang Syndrome.. <i>Endocrine Practice</i> , <b>2022</b> ,	3.2	
485	Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma.. <i>European Journal of Cancer</i> , <b>2022</b> , 169, 32-41	7.5	0
484	Supportive management of patients with pheochromocytoma/paraganglioma undergoing noninvasive treatment. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , <b>2022</b> , 29, 294-301	4	0
483	Differences in clinical presentation and management between pre- and postsurgical diagnoses of urinary bladder paraganglioma: is there clinical relevance? A systematic review. <i>World Journal of Urology</i> , <b>2021</b> ,	4	2
482	Developmental vascular malformations in EPAS1 gain-of-function syndrome. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	3
481	High-Specific-Activity-I-MIBG versus Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2989-2995	12.9	8
480	Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
479	Succinate Mediates Tumorigenic Effects Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 589451	5.7	6
478	Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 625312	5.7	5
477	Imaging of Small Intestine Neuroendocrine Neoplasms: Is SSTR PET the Holy Grail?. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 1347-1348	8.9	1
476	Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 3303-3312	7.4	1
475	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. <i>Nature Reviews Endocrinology</i> , <b>2021</b> , 17, 435-444	15.2	12
474	Personalized management of pheochromocytoma and paraganglioma. <i>Endocrine Reviews</i> , <b>2021</b> ,	27.2	18
473	Diagnostic Accuracy of Salivary Metanephrines in Pheochromocytomas and Paragangliomas. <i>Clinical Chemistry</i> , <b>2021</b> , 67, 1090-1097	5.5	0
472	Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
471	Imaging of Pheochromocytoma and Paraganglioma. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 1033-1042	8.9	12

470	C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23. <i>Journal of Bone and Mineral Research</i> , <b>2021</b> , 36, 315-321	6.3	3
469	Phaeochromocytoma and pregnancy: looking towards better outcomes, less fear, and valuable recommendations. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> , 9, 2-3	18.1	2
468	What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?. <i>Endocrine Pathology</i> , <b>2021</b> , 32, 134-153	4.2	7
467	Pheochromocytoma Hypertensive Crisis. <i>Contemporary Endocrinology</i> , <b>2021</b> , 137-145	0.3	
466	Functional significance of germline EPAS1 variants. <i>Endocrine-Related Cancer</i> , <b>2021</b> , 28, 97-109	5.7	1
465	A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 26S-33S	8.9	3
464	Sporadic Primary Pheochromocytoma: A Prospective Intra-Individual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using Ga-DOTATATE, FDG, F-FDOPA, and F-FDA). <i>American Journal of Roentgenology</i> , <b>2021</b> ,	5.4	2
463	Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
462	Germline SUCLG2 Variants in Patients with Pheochromocytoma and Paraganglioma. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	4
461	Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma. <i>Frontiers in Endocrinology</i> , <b>2021</b> , 12, 731096	5.7	0
460	Variants and Pitfalls of PET/CT in Neuroendocrine Tumors. <i>Seminars in Nuclear Medicine</i> , <b>2021</b> , 51, 519-528	5.8	4
459	A long noncoding RNA-microRNA expression signature predicts metastatic signature in pheochromocytomas and paragangliomas. <i>Endocrine</i> , <b>2021</b> , 1	4	0
458	Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. <i>Journal of Nuclear Medicine</i> , <b>2021</b> , 62, 1192-1199	8.9	1
457	A novel liquid biopsy (NETest) identifies paragangliomas and pheochromocytomas with high accuracy. <i>Endocrine-Related Cancer</i> , <b>2021</b> , 28, 731-744	5.7	1
456	Quantitative biomarkers allow the diagnosis of head and neck paraganglioma on multiparametric MRI. <i>European Journal of Radiology</i> , <b>2021</b> , 143, 109911	4.7	0
455	The Global Reading Room: Nuclear Medicine Imaging of Suspected Paraganglioma. <i>American Journal of Roentgenology</i> , <b>2021</b> , 217, 1008-1009	5.4	0
454	Neuraxial dysraphism in associated syndrome due to improper mesenchymal transition. <i>Neurology: Genetics</i> , <b>2020</b> , 6, e414	3.8	2
453	Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas. <i>Journal of Pathology</i> , <b>2020</b> , 251, 378-387	9.4	11

452	Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. <i>Metabolism: Clinical and Experimental</i> , <b>2020</b> , 110, 154297	12.7	3
451	Therapeutic Targeting of -Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 3868-3880	12.9	12
450	Genetics, diagnosis, management and future directions of research of pheochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. <i>Journal of Hypertension</i> , <b>2020</b> , 38, 1443-1456	1.9	62
449	Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 1051-1063	4.9	14
448	Clinical manifestations of Pacak-Zhuang syndrome in a male pediatric patient. <i>Pediatric Blood and Cancer</i> , <b>2020</b> , 67, e28096	3	0
447	Role of Ga-DOTATATE PET/CT in a Case of -Related Pterygopalatine Fossa Paraganglioma Successfully Controlled with Octreotide. <i>Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 54, 48-52	1.9	4
446	Targeting NRF2-Governed Glutathione Synthesis for -Mutated Pheochromocytoma and Paraganglioma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	15
445	Comprehensive review of evaluation and management of cardiac paragangliomas. <i>Heart</i> , <b>2020</b> , 106, 1203-1210	5.2	5
444	A xenograft and cell line model of SDH-deficient pheochromocytoma derived from Sdhb+/- rats. <i>Endocrine-Related Cancer</i> , <b>2020</b> , 27, 337-354	5.7	9
443	Epidural anesthesia and hypotension in pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , <b>2020</b> , 27, 519-527	5.7	2
442	HIF2 $\beta$ supports pro-metastatic behavior in pheochromocytomas/paragangliomas. <i>Endocrine-Related Cancer</i> , <b>2020</b> , 27, 625-640	5.7	12
441	<sup>18</sup> F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , <b>2020</b> , 2020,	1.4	2
440	A novel germline gain-of-function HIF2A mutation in hepatocellular carcinoma with polycythemia. <i>Aging</i> , <b>2020</b> , 12, 5781-5791	5.6	0
439	Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. <i>Gland Surgery</i> , <b>2020</b> , 9, 105-123	2.2	21
438	Prognostic and predictive value of nuclear imaging in endocrine oncology. <i>Endocrine</i> , <b>2020</b> , 67, 9-19	4	4
437	Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome. <i>JAMA Ophthalmology</i> , <b>2020</b> , 138, 148-155	3.9	4
436	Some Considerations in Treating Malignant Head and Neck Paragangliomas. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2020</b> , 146, 209-210	3.9	2
435	Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	8

434	Phosphoprotein-based biomarkers as predictors for cancer therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 18401-18411	11.5	10
433	Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 451-464	15.1	11
432	Induction of Immune Response Against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibody (MBTA). <i>Advanced Therapeutics</i> , <b>2020</b> , 3, 2000044	4.9	3
431	Catecholamine physiology and its implications in patients with COVID-19. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 978-986	18.1	19
430	Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. <i>Current Treatment Options in Oncology</i> , <b>2020</b> , 21, 85	5.4	18
429	Phaeochromocytoma - advances through science, collaboration and spreading the word. <i>Nature Reviews Endocrinology</i> , <b>2020</b> , 16, 621-622	15.2	4
428	Surgical Resection of Pheochromocytomas and Paragangliomas is Associated with Lower Cholesterol Levels. <i>World Journal of Surgery</i> , <b>2020</b> , 44, 552-560	3.3	2
427	Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 2326-2335	7.5	10
426	Retraction Note to: Carboxypeptidase E: Elevated Expression Correlated with Tumor Growth and Metastasis in Pheochromocytomas and Other Cancers. <i>Cellular and Molecular Neurobiology</i> , <b>2020</b> , 40, 859	4.6	1
425	Genetic Determinants of Pheochromocytoma and Paraganglioma Imaging Phenotypes. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 643-645	8.9	4
424	Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma. <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 587065	5.7	0
423	Tumor multifocality with vagus nerve involvement as a phenotypic marker of SDHD mutation in patients with head and neck paragangliomas: A F-FDOPA PET/CT study. <i>Head and Neck</i> , <b>2019</b> , 41, 1565-1571	14.7	1
422	Exploring the link between tumour metabolism and succinate dehydrogenase deficiency: A F-FDOPA PET/CT study in head and neck paragangliomas. <i>Clinical Endocrinology</i> , <b>2019</b> , 91, 879-884	3.4	2
421	Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. <i>Endocrinology</i> , <b>2019</b> , 160, 2600-2617	4.8	12
420	Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. <i>Cancers</i> , <b>2019</b> , 11,	6.6	13
419	More on Ivabradine in Tachycardia with Paraganglioma. Reply. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 2590	59.2	
418	MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas. <i>Journal of Surgical Research</i> , <b>2019</b> , 243, 1-7	2.5	8
417	Chiari Malformation Type 1 in -Associated Syndrome. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	6

416	A Transgenic Mouse Model of Pacak-Zhuang Syndrome with An Gain-of-Function Mutation. <i>Cancers</i> , <b>2019</b> , 11,	6.6	12
415	Gallbladder Paraganglioma Associated with Mutation: a Potential Pitfall on F-FDOPA PET Imaging. <i>Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 53, 144-147	1.9	4
414	Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2 $\beta$ in Pheochromocytoma Cells. <i>Cancers</i> , <b>2019</b> , 11,	6.6	14
413	The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40. <i>Cancers</i> , <b>2019</b> , 11,	6.6	11
412	A Previously Unrecognized Monocytic Component of Pheochromocytoma and Paraganglioma. <i>Endocrine Pathology</i> , <b>2019</b> , 30, 90-95	4.2	6
411	Deficiency in the dorsomedial hypothalamus leads to obesity, hyperphagia, and reduced thermogenesis associated with impaired leptin signaling. <i>Molecular Metabolism</i> , <b>2019</b> , 25, 142-153	8.8	4
410	A NECESSITY, NOT A SECOND THOUGHT: PRE-OPERATIVE ALPHA-ADRENOCEPTOR BLOCKADE IN PHEOCHROMOCYTOMA PATIENTS. <i>Endocrine Practice</i> , <b>2019</b> , 25, 200-201	3.2	0
409	Clinical, Diagnostic, and Treatment Characteristics of $\beta$ -Related Metastatic Pheochromocytoma and Paraganglioma. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 53	5.3	24
408	Ivabradine in Catecholamine-Induced Tachycardia in a Patient with Paraganglioma. <i>New England Journal of Medicine</i> , <b>2019</b> , 380, 1284-1286	59.2	6
407	Eruption of Metastatic Paraganglioma After Successful Therapy with Lu/Y-DOTATOC and Lu-DOTATATE. <i>Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 53, 223-230	1.9	6
406	Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies. <i>Cancers</i> , <b>2019</b> , 11,	6.6	21
405	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. <i>Genetics in Medicine</i> , <b>2019</b> , 21, 705-717	8.1	36
404	Postoperative Management in Patients with Pheochromocytoma and Paraganglioma. <i>Cancers</i> , <b>2019</b> , 11,	6.6	15
403	Medullary Thyroid Carcinoma: An Update on Imaging. <i>Journal of Thyroid Research</i> , <b>2019</b> , 2019, 1893047	2.6	19
402	European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2019</b> , 46, 2112-2137	8.8	113
401	Adipocyte $\beta$ -arrestin-2 is essential for maintaining whole body glucose and energy homeostasis. <i>Nature Communications</i> , <b>2019</b> , 10, 2936	17.4	27
400	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. <i>Cancers</i> , <b>2019</b> , 11,	6.6	65
399	Pseudopheochromocytoma. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2019</b> , 48, 751-764	5.5	3



398	Coley <sup>B</sup> immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity. <i>Seminars in Oncology</i> , <b>2019</b> , 46, 385-392	5.5	4
397	A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position. <i>European Journal of Endocrinology</i> , <b>2019</b> , 181, 301-309	6.5	12
396	Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis. <i>Endocrine-Related Cancer</i> , <b>2019</b> , 26, 539-550	5.7	47
395	Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. <i>Endocrine-Related Cancer</i> , <b>2019</b> , 26, R627-R652	5.7	39
394	Characteristic CT features of pheochromocytomas - probability model calculation tool based on a multicentric study. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , <b>2019</b> , 163, 212-219	1.7	11
393	Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: How to Manage a Rare Complication in a Rare Disease?. <i>Hormone and Metabolic Research</i> , <b>2019</b> , 51, 458-469	3.1	24
392	Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells. <i>Cell Metabolism</i> , <b>2019</b> , 29, 399-416.e10	24.6	104
391	Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndrome. <i>Cancer</i> , <b>2019</b> , 125, 1258-1266	6.4	8
390	The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors. <i>Hormone and Metabolic Research</i> , <b>2019</b> , 51, 419-436	3.1	14
389	Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2019</b> , 127, 117-128	2.3	25
388	WHY TAKE THE RISK? WE ONLY LIVE ONCE: THE DANGERS ASSOCIATED WITH NEGLECTING A PRE-OPERATIVE ALPHA ADRENOCEPTOR BLOCKADE IN PHEOCHROMOCYTOMA PATIENTS. <i>Endocrine Practice</i> , <b>2019</b> , 25, 106-108	3.2	9
387	Radioguided Surgery With Gallium 68 Dotatate for Patients With Neuroendocrine Tumors. <i>JAMA Surgery</i> , <b>2019</b> , 154, 40-45	5.4	23
386	Preoperative 18F-FDG PET/CT in Pheochromocytomas and Paragangliomas Allows for Precision Surgery. <i>Annals of Surgery</i> , <b>2019</b> , 269, 741-747	7.8	11
385	Diagnostic Investigation of Lesions Associated with Succinate Dehydrogenase Defects. <i>Hormone and Metabolic Research</i> , <b>2019</b> , 51, 414-418	3.1	3
384	18F-FDOPA PET/CT Imaging of MAX-Related Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 1574-1582	5.6	17
383	Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy. <i>Cellular and Molecular Neurobiology</i> , <b>2018</b> , 38, 1099-1106	4.6	13
382	Targeting NAD/PARP DNA Repair Pathway as a Novel Therapeutic Approach to -Mutated Cluster I Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3423-3432	12.9	38
381	Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. <i>Cell and Tissue Research</i> , <b>2018</b> , 372, 393-401	4.2	23

380	Successful induction therapy with sequential CVD followed by high-dose lanreotide in for metastatic SDHB paraganglioma: Case report. <i>Journal of Clinical and Translational Endocrinology: Case Reports</i> , <b>2018</b> , 7, 8-13	0.5	2
379	Genomic Landscape of Pheochromocytoma and Paraganglioma. <i>Trends in Cancer</i> , <b>2018</b> , 4, 6-9	12.5	47
378	Prognostic Utility of Total Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors. <i>Gastroenterology</i> , <b>2018</b> , 154, 998-1008.e1	13.3	39
377	Deletion of the von Hippel-Lindau Gene in Hemangioblasts Causes Hemangioblastoma-like Lesions in Murine Retina. <i>Cancer Research</i> , <b>2018</b> , 78, 1266-1274	10.1	15
376	Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature. <i>Clinical Medicine Insights: Oncology</i> , <b>2018</b> , 12, 1179554918763367	1.8	15
375	A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2 positive polycythemia vera: a case report. <i>BMC Cancer</i> , <b>2018</b> , 18, 286	4.8	12
374	Pheochromocytoma/Paraganglioma: Update on Diagnosis and Management. <i>Contemporary Endocrinology</i> , <b>2018</b> , 261-310	0.3	2
373	Quantitative F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 278-282	8.8	20
372	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. <i>Genetics in Medicine</i> , <b>2018</b> , 20, 1652-1662	8.1	33
371	Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging. <i>Frontiers in Endocrinology</i> , <b>2018</b> , 9, 515	5.7	53
370	Mathematical modeling of disease dynamics in SDHB- and SDHD-related paraganglioma: Further step in understanding hereditary tumor differences and future therapeutic strategies. <i>PLoS ONE</i> , <b>2018</b> , 13, e0201303	3.7	3
369	The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance. <i>Endocrine-Related Cancer</i> , <b>2018</b> , 25, 893-908	5.7	14
368	Alternative assembly of respiratory complex II connects energy stress to metabolic checkpoints. <i>Nature Communications</i> , <b>2018</b> , 9, 2221	17.4	29
367	Superiority of Ga-DOTATATE over F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 787-797	8.8	38
366	Preoperative genetic testing in pheochromocytomas and paragangliomas influences the surgical approach and the extent of adrenal surgery. <i>Surgery</i> , <b>2018</b> , 163, 191-196	3.6	21
365	Blood collection in unstressed, conscious, and freely moving mice through implantation of catheters in the jugular vein: a new simplified protocol. <i>Physiological Reports</i> , <b>2018</b> , 6, e13904	2.6	6
364	RNA-Sequencing Analysis of Adrenocortical Carcinoma, Pheochromocytoma and Paraganglioma from a Pan-Cancer Perspective. <i>Cancers</i> , <b>2018</b> , 10,	6.6	5
363	New insights on the pathogenesis of paraganglioma and pheochromocytoma. <i>F1000Research</i> , <b>2018</b> , 7,	3.6	14



362	SDHD Gene Mutations: Looking Beyond Head and Neck Tumors. <i>AACE Clinical Case Reports</i> , <b>2018</b> , 4, 186-190		
361	Primary fibroblast co-culture stimulates growth and metabolism in Sdhb-impaired mouse pheochromocytoma MTT cells. <i>Cell and Tissue Research</i> , <b>2018</b> , 374, 473-485	4.2	12
360	Prospective evaluation of Ga-DOTATATE PET/CT in limited disease neuroendocrine tumours and/or elevated serum neuroendocrine biomarkers. <i>Clinical Endocrinology</i> , <b>2018</b> , 89, 155-163	3.4	9
359	Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations. <i>Endocrine</i> , <b>2018</b> , 61, 216-223	4	4
358	A Clinical Roadmap to Investigate the Genetic Basis of Pediatric Pheochromocytoma: Which Genes Should Physicians Think About?. <i>International Journal of Endocrinology</i> , <b>2018</b> , 2018, 8470642	2.7	8
357	Leptomeningeal dissemination of a low-grade lumbar paraganglioma: case report. <i>Journal of Neurosurgery: Spine</i> , <b>2017</b> , 26, 501-506	2.8	8
356	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , <b>2017</b> , 31, 181-193	24.3	350
355	Radionuclide Imaging of Head and Neck Paragangliomas <b>2017</b> , 269-294		
354	Implications of SDHB genetic testing in patients with sporadic pheochromocytoma. <i>Langenbeck's Archives of Surgery</i> , <b>2017</b> , 402, 787-798	3.4	2
353	Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 523-528	2.2	39
352	Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma. <i>FASEB Journal</i> , <b>2017</b> , 31, 2226-2240	0.9	7
351	Mitochondrial Complex II: At the Crossroads. <i>Trends in Biochemical Sciences</i> , <b>2017</b> , 42, 312-325	10.3	122
350	Paraganglioma of the organ of Zuckerkandl associated with a somatic mutation: A case report. <i>Oncology Letters</i> , <b>2017</b> , 13, 1083-1086	2.6	2
349	Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review. <i>Endocrine</i> , <b>2017</b> , 56, 495-503	4	59
348	Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 1122-1132	5.6	87
347	F-fluorodihydroxyphenylalanine PET/CT in pheochromocytoma and paraganglioma: relation to genotype and amino acid transport system L. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 812-821	8.8	13
346	The Evolving Role of Succinate in Tumor Metabolism: An F-FDG-Based Study. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1749-1755	8.9	22
345	SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2017</b> , 143, 1421-1435	4.9	43

344	Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1236-1242	8.9	24
343	PRECISION MEDICINE IN ADRENAL DISORDERS: THE NEXT GENERATION. <i>Endocrine Practice</i> , <b>2017</b> , 23, 672-679	3.2	2
342	PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS. <i>Endocrine Practice</i> , <b>2017</b> , 23, 690-704	3.2	36
341	Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total Ga-DOTATATE-Avid tumor volume measurements. <i>European Journal of Endocrinology</i> , <b>2017</b> , 176, 575-582	6.5	30
340	Radionuclide Imaging of Chromaffin Cell Tumors <b>2017</b> , 295-319		
339	HIF-2alpha: AchillesPheel of pseudohypoxic subtype paraganglioma and other related conditions. <i>European Journal of Cancer</i> , <b>2017</b> , 86, 1-4	7.5	13
338	Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice. <i>Endocrinology</i> , <b>2017</b> , 158, 3097-3108	4.8	10
337	Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway. <i>Oncotarget</i> , <b>2017</b> , 8, 22313-22324	3.3	21
336	The microenvironment induces collective migration in -silenced mouse pheochromocytoma spheroids. <i>Endocrine-Related Cancer</i> , <b>2017</b> , 24, 555-564	5.7	19
335	New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma. <i>Trends in Endocrinology and Metabolism</i> , <b>2017</b> , 28, 807-817	8.8	22
334	Metanephrines for Evaluating Palpitations and Flushing. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 385-386	27.4	5
333	Mapping of human brown adipose tissue in lean and obese young men. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 8649-8654	11.5	224
332	Relevant Discordance Between 68Ga-DOTATATE and 68Ga-DOTANOC in SDHB-Related Metastatic Paraganglioma: Is Affinity to Somatostatin Receptor 2 the Key?. <i>Clinical Nuclear Medicine</i> , <b>2017</b> , 42, 211-213	1.7	3
331	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. <i>Endocrine Reviews</i> , <b>2017</b> , 38, 489-515	27.2	151
330	Recent advances in the imaging of pheochromocytomas and paragangliomas. <i>International Journal of Endocrine Oncology</i> , <b>2017</b> , 4, 137-144	0.3	
329	PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics. <i>Journal of Molecular Diagnostics</i> , <b>2017</b> , 19, 575-588	5.1	51
328	Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation. <i>Endocrine Pathology</i> , <b>2017</b> , 28, 302-307	4.2	16
327	SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma. <i>Surgery</i> , <b>2017</b> , 161, 230-239	3.6	43

326 Management of Pheochromocytoma and Paraganglioma **2017**, 179-206

325 Reply: 68Ga-DOTATATE PET/CT Versus MRI: Why the Comparison of 68Ga-DOTATATE PET/CT to an Appropriate MRI Protocol Is Essential. *Journal of Nuclear Medicine*, **2017**, 58, 185 8.9 3

324 Imaging Modalities for Pheochromocytoma and Paraganglioma **2017**, 125-138

323 Pathology of Human Pheochromocytoma and Paraganglioma Xenografts in NSG Mice. *Endocrine Pathology*, **2017**, 28, 2-6 4.2 10

322 Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. *Surgery*, **2017**, 161, 220-227 3.6 38

321 Cardiometabolic risk factors and health behaviors in family caregivers. *PLoS ONE*, **2017**, 12, e0176408 3.7 5

320 Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. *Oncotarget*, **2017**, 8, 56110-56125 3.3 39

319 Carney triad can be (rarely) associated with germline succinate dehydrogenase defects. *European Journal of Human Genetics*, **2016**, 24, 569-73 5.3 45

318 Uncommon spreading of primary malignant paraganglioma in a patient with SDHB mutation. *Case Reports in Internal Medicine*, **2016**, 4, 63 0

317 The Author's Reply: inappropriate adrenoreceptor blockade prior to pheochromocytoma removal - A timely reappraisal. *Clinical Endocrinology*, **2016**, 85, 990-991 3.4

316 Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. *Journal of Nuclear Medicine*, **2016**, 57, 1949-1956 8.9 89

315 AN AGGRESSIVE TEMPORAL BONE SDHC PARAGANGLIOMA ASSOCIATED WITH INCREASED HIF-2 $\alpha$  SIGNALING. *Endocrine Practice*, **2016**, 22, 190-5 3.2 4

314 Functional Imaging Experience in a Germline Fumarate Hydratase Mutation-Positive Patient With Pheochromocytoma and Paraganglioma. *AACE Clinical Case Reports*, **2016**, 2, e176-e181 0.7 6

313 CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY. *Endocrine Practice*, **2016**, 22, 302-14 3.2 76

312 Are patients with hormonally functional pheochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study. *Clinical Endocrinology*, **2016**, 85, 62-9 3.4 11

311 Rapidly Growing Chest Wall Mass in a Case of Sporadic Metastatic Paraganglioma: Imaging With 4 Different PET Radiopharmaceuticals. *Clinical Nuclear Medicine*, **2016**, 41, 399-400 1.7 1

310 PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2016**, 43, 1784-91 8.8 106

309 Molecular Subtypes of KIT/PDGFR $\alpha$  Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. *JAMA Oncology*, **2016**, 2, 922-8 13.4 187

308	Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. <i>Journal of Neuro-Oncology</i> , <b>2016</b> , 126, 473-81	4.8	15
307	In vivo detection of catecholamines by magnetic resonance spectroscopy: A potential specific biomarker for the diagnosis of pheochromocytoma. <i>Surgery</i> , <b>2016</b> , 159, 1231-3	3.6	9
306	Documenting stress in caregivers of transplantation patients: initial evidence of HPA dysregulation. <i>Stress</i> , <b>2016</b> , 19, 175-84	3	21
305	Mass spectrometric quantification of salivary metanephrines-A study in healthy subjects. <i>Clinical Biochemistry</i> , <b>2016</b> , 49, 983-8	3.5	6
304	Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 1248-57	8.8	80
303	Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 588-96	2.2	210
302	68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 186-91	8.9	120
301	Determination of the unmetabolised (18)F-FDG fraction by using an extension of simplified kinetic analysis method: clinical evaluation in paragangliomas. <i>Medical and Biological Engineering and Computing</i> , <b>2016</b> , 54, 103-11	3.1	9
300	Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models. <i>Oncotarget</i> , <b>2016</b> , 7, 40531-40545	3.3	9
299	Pheochromocytoma Resection: The Rule of Surgical Divergence. <i>AACE Clinical Case Reports</i> , <b>2016</b> , 2, e78e79		1
298	Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas. <i>Annals of Surgery</i> , <b>2016</b> , 263, 582-7	7.8	7
297	(18)F-DOPA: the versatile radiopharmaceutical. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2016</b> , 43, 1187-9	8.8	8
296	Endocrine tumors associated with the vagus nerve. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, R371-9	5.7	6
295	Hypoxia-Inducible Factor 2 $\mu$ Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. <i>Neoplasia</i> , <b>2016</b> , 18, 567-76	6.4	13
294	Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, 899-908	5.7	49
293	HIF2A gain-of-function mutations detected in duodenal gangliocytic paraganglioma. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, L13-6	5.7	15
292	Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, E710-9	5.6	102
291	Results of (68)Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1. <i>Journal of the American College of Surgeons</i> , <b>2015</b> , 221, 509-17	4.4	56

290	Pheochromocytoma and Paraganglioma Syndromes <b>2015</b> , 449-454		2
289	Pheochromocytoma: Gasping for Air. <i>Hormones and Cancer</i> , <b>2015</b> , 6, 191-205	5	22
288	Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics. <i>Endocrine-Related Cancer</i> , <b>2015</b> , 22, M1-8	5.7	26
287	Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 167.e13-20	2.8	18
286	Preoperative Imaging Features are Associated with Surgical Complications Following Carotid Body Tumor Resection. <i>World Journal of Surgery</i> , <b>2015</b> , 39, 2084-9	3.3	10
285	Succinate dehydrogenase gene mutations in cardiac paragangliomas. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 1753-9	3	22
284	Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3888-95	12.9	175
283	Pheochromocytoma and paraganglioma. <i>Endocrine Practice</i> , <b>2015</b> , 21, 406-12	3.2	43
282	18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 1849-54	8.9	3
281	Carney triad, SDH-deficient tumors, and Sdhb+/- mice share abnormal mitochondria. <i>Endocrine-Related Cancer</i> , <b>2015</b> , 22, 345-52	5.7	21
280	Pendrin localizes to the adrenal medulla and modulates catecholamine release. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2015</b> , 309, E534-45	6	17
279	Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. <i>PET Clinics</i> , <b>2015</b> , 10, 477-86	2.2	10
278	Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells. <i>Endocrinology</i> , <b>2015</b> , 156, 4094-104	4.8	8
277	15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , <b>2015</b> , 22, T135-45	5.7	65
276	Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. <i>Journal of Molecular Medicine</i> , <b>2015</b> , 93, 93-104	5.5	92
275	Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia. <i>Human Genome Variation</i> , <b>2015</b> , 2, 15053	1.8	21
274	Multidisciplinary management of locally advanced and widely metastatic paraganglioma in a patient with life-threatening compressive symptoms. <i>Head and Neck</i> , <b>2015</b> , 37, E205-8	4.2	1
273	Urinary Bladder Paragangliomas: How Immunohistochemistry Can Assist to Identify Patients With SDHB Germline and Somatic Mutations. <i>American Journal of Surgical Pathology</i> , <b>2015</b> , 39, 1488-92	6.7	15

272	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). <i>Modern Pathology</i> , <b>2015</b> , 28, 807-21	9.8	142
271	Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma. <i>European Journal of Endocrinology</i> , <b>2015</b> , 172, 89-95	6.5	13
270	Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 4498-504	5.6	46
269	Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications. <i>Neoplasia</i> , <b>2015</b> , 17, 55-65	6.4	49
268	Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells. <i>American Journal of Cancer Research</i> , <b>2015</b> , 5, 1558-70	4.4	10
267	The genetic basis of pheochromocytoma and paraganglioma: implications for management. <i>Urology</i> , <b>2014</b> , 83, 1225-32	1.6	33
266	Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. <i>Cell Metabolism</i> , <b>2014</b> , 19, 302-9	24.6	513
265	Familial pheochromocytomas and paragangliomas. <i>Molecular and Cellular Endocrinology</i> , <b>2014</b> , 386, 92-100	4.4	42
264	Genetics, diagnosis, and management of medullary thyroid carcinoma and pheochromocytoma/paraganglioma. <i>Endocrine Practice</i> , <b>2014</b> , 20, 176-87	3.2	11
263	Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. <i>Current Problems in Cancer</i> , <b>2014</b> , 38, 7-41	2.3	132
262	Ocular manifestations of hypoxia-inducible factor-2 $\beta$ paraganglioma-somatostatinoma-polycythemia syndrome. <i>Ophthalmology</i> , <b>2014</b> , 121, 2291-3	7.3	21
261	Current approaches and recent developments in the management of head and neck paragangliomas. <i>Endocrine Reviews</i> , <b>2014</b> , 35, 795-819	27.2	94
260	Opposing effects of HIF1 $\alpha$ and HIF2 $\alpha$ on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 2054-64	7.5	54
259	Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma. <i>Journal of Nuclear Medicine</i> , <b>2014</b> , 55, 1253-9	8.9	52
258	Renaissance of (18)F-FDG positron emission tomography in the imaging of pheochromocytoma/paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 2337-9	5.6	16
257	The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study. <i>BMC Cancer</i> , <b>2014</b> , 14, 523	4.8	36
256	Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 1915-42	5.6	1415
255	Association between acute sympathetic response, early onset vasospasm, and delayed vasospasm following spontaneous subarachnoid hemorrhage. <i>Journal of Clinical Neuroscience</i> , <b>2014</b> , 21, 256-62	2.2	13



254	The presence of SDHB mutations should modify surgical indications for carotid body paragangliomas. <i>Annals of Surgery</i> , <b>2014</b> , 260, 158-62	7.8	35
253	High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paraganglioma. <i>PLoS ONE</i> , <b>2014</b> , 9, e90458	3.7	7
252	Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines. <i>PLoS ONE</i> , <b>2014</b> , 9, e87807	3.7	10
251	ZNF367 inhibits cancer progression and is targeted by miR-195. <i>PLoS ONE</i> , <b>2014</b> , 9, e101423	3.7	29
250	Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 3903-11	5.6	83
249	Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2014</b> , 138, 182-8	5	44
248	External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 166	5.3	37
247	Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB/D-related paraganglioma: initial experimental and ex vivo findings. <i>Endocrinology</i> , <b>2014</b> , 155, 27-32	4.8	51
246	Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice. <i>Endocrinology</i> , <b>2014</b> , 155, 2377-90	4.8	14
245	Counseling patients with succinate dehydrogenase subunit defects: genetics, preventive guidelines, and dealing with uncertainty. <i>Journal of Pediatric Endocrinology and Metabolism</i> , <b>2014</b> , 27, 837-44	1.6	6
244	18F-FDG PET/CT as a predictor of hereditary head and neck paragangliomas. <i>European Journal of Clinical Investigation</i> , <b>2014</b> , 44, 325-332	4.6	24
243	Clinical utility of chromogranin A in SDHx-related paragangliomas. <i>European Journal of Clinical Investigation</i> , <b>2014</b> , 44, 365-71	4.6	33
242	Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. <i>Clinical Endocrinology</i> , <b>2014</b> , 81, 317-28	3.4	21
241	Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol. <i>Clinical Nuclear Medicine</i> , <b>2014</b> , 39, 243-50	1.7	16
240	Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , <b>2014</b> , 21, R261-77	5.7	28
239	Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. <i>Antioxidants and Redox Signaling</i> , <b>2014</b> , 20, 267-80	8.4	112
238	The adrenal medulla and extra-adrenal paraganglia: then and now. <i>Endocrine Pathology</i> , <b>2014</b> , 25, 49-58	4.2	30
237	Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells. <i>PLoS ONE</i> , <b>2014</b> , 9, e97712	3.7	17

236	Pheochromocytoma Hypertensive Crisis <b>2014</b> , 139-147		1
235	A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. <i>Journal of Molecular Medicine</i> , <b>2013</b> , 91, 507-12	5.5	134
234	Double stable isotope ultra performance liquid chromatographic-tandem mass spectrometric quantification of tissue content and activity of phenylethanolamine N-methyltransferase, the crucial enzyme responsible for synthesis of epinephrine. <i>Analytical and Bioanalytical Chemistry</i> , <b>2013</b> , 405, 1713-9	4.4	4
233	Landscape of the mitochondrial Hsp90 metabolome in tumours. <i>Nature Communications</i> , <b>2013</b> , 4, 2139	17.4	104
232	Multitracer PET imaging of bone metastases from paraganglioma: peripheral halo of uptake on 18F-FLT PET mismatching with central uptake of 18F-FDOPA, 18F-fluorodopamine, and 18F-FDG. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2013</b> , 40, 1928-9	8.8	1
231	Association between sympathetic response, neurogenic cardiomyopathy, and venous thromboembolization in patients with primary subarachnoid hemorrhage. <i>Acta Neurochirurgica</i> , <b>2013</b> , 155, 1501-10	3	6
230	Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?. <i>Journal of the American College of Surgeons</i> , <b>2013</b> , 217, 489-96	4.4	34
229	Plasma-free vs deconjugated metanephrines for diagnosis of pheochromocytoma. <i>Clinical Endocrinology</i> , <b>2013</b> , 79, 476-83	3.4	15
228	Role of hypoxia and HIF2 $\beta$ in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features. <i>Advances in Pharmacology</i> , <b>2013</b> , 68, 285-317	5.7	30
227	Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. <i>Blood</i> , <b>2013</b> , 121, 2563-6	2.2	75
226	Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of pheochromocytoma. <i>Annals of Clinical Biochemistry</i> , <b>2013</b> , 50, 62-9	2.2	77
225	Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 966-71	11.5	54
224	Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas. <i>Neoplasia</i> , <b>2013</b> , 15, 435-47	6.4	25
223	Current and future trends in the anatomical and functional imaging of head and neck paragangliomas. <i>Seminars in Nuclear Medicine</i> , <b>2013</b> , 43, 462-73	5.4	15
222	Pheochromocytoma: Unmasking the Chameleon <b>2013</b> , 123-148		2
221	Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. <i>Endocrinology</i> , <b>2013</b> , 154, 646-55	4.8	38
220	First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, E908-13	5.6	49
219	Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , <b>2013</b> , 20, 186-91	4	43

218	Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3787-95	12.9	38
217	Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. <i>Cancer Discovery</i> , <b>2013</b> , 3, 648-57	24.4	228
216	Commentary. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 1565	5.5	
215	New syndrome of paraganglioma and somatostatinoma associated with polycythemia. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1690-8	2.2	112
214	Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1270-83	9.7	122
213	Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18)F-FDOPA PET: focus on missed lesions. <i>Clinical Endocrinology</i> , <b>2013</b> , 79, 170-7	3.4	43
212	Phospho-mTOR is not upregulated in metastatic SDHB paragangliomas. <i>European Journal of Clinical Investigation</i> , <b>2013</b> , 43, 970-7	4.6	7
211	Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. <i>PLoS ONE</i> , <b>2013</b> , 8, e56083	3.7	20
210	A new specific succinate-glutamate metabolomic hallmark in SDHx-related paragangliomas. <i>PLoS ONE</i> , <b>2013</b> , 8, e80539	3.7	32
209	Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH?. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, E357-66	5.6	116
208	Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. <i>Journal of Urology</i> , <b>2012</b> , 188, 2063-71	2.5	175
207	Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma. <i>Nuclear Medicine and Biology</i> , <b>2012</b> , 39, 215-26	2.1	12
206	Subclinical phaeochromocytoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 26, 507-15	6.5	59
205	Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging. <i>Cancer Letters</i> , <b>2012</b> , 316, 46-52	9.9	17
204	Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 1739-49	7.5	228
203	NF-B inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 2445-55	7.5	27
202	Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. <i>FASEB Journal</i> , <b>2012</b> , 26, 4506-16	0.9	33
201	New roles of carboxypeptidase E in endocrine and neural function and cancer. <i>Endocrine Reviews</i> , <b>2012</b> , 33, 216-53	27.2	73

200	EANM 2012 guidelines for radionuclide imaging of pheochromocytoma and paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2012</b> , 39, 1977-95	8.8	193
199	Warburg effect <sup>B</sup> manifestation in aggressive pheochromocytomas and paragangliomas: insights from a mouse cell model applied to human tumor tissue. <i>PLoS ONE</i> , <b>2012</b> , 7, e40949	3.7	27
198	Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies?. <i>Endocrine Pathology</i> , <b>2012</b> , 23, 43-54	4.2	19
197	Determinants of central sympathetic activation in spontaneous primary subarachnoid hemorrhage. <i>Neurocritical Care</i> , <b>2012</b> , 16, 381-8	3.3	23
196	False-negative <sup>111</sup> In-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease. <i>Endocrine-Related Cancer</i> , <b>2012</b> , 19, 83-93	5.7	80
195	Combined blockade of signalling pathways shows marked anti-tumour potential in pheochromocytoma cell lines. <i>Journal of Molecular Endocrinology</i> , <b>2012</b> , 49, 79-96	4.5	41
194	Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 700-8	9.7	197
193	Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 922-30	59.2	288
192	MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2828-37	12.9	226
191	Cerebrospinal fluid catecholamine levels as predictors of outcome in subarachnoid hemorrhage. <i>Cerebrovascular Diseases</i> , <b>2012</b> , 33, 173-81	3.2	22
190	Pheochromocytoma and paraganglioma: current functional and future molecular imaging. <i>Frontiers in Oncology</i> , <b>2011</b> , 1, 58	5.3	30
189	Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer. <i>Seminars in Nuclear Medicine</i> , <b>2011</b> , 41, 364-8	5.4	51
188	When is a phaeo not a phaeo? Depression in an adolescent leading to a pheochromocytoma-like biochemical profile. <i>Clinical Endocrinology</i> , <b>2011</b> , 75, 567-8	3.4	1
187	Metastatic pheochromocytoma: does the size and age matter?. <i>European Journal of Clinical Investigation</i> , <b>2011</b> , 41, 1121-8	4.6	33
186	Comparison of clinical and imaging features in succinate dehydrogenase-positive versus sporadic paragangliomas. <i>Surgery</i> , <b>2011</b> , 150, 1186-93	3.6	13
185	CSF catecholamine profile in subarachnoid hemorrhage patients with neurogenic cardiomyopathy. <i>Neurocritical Care</i> , <b>2011</b> , 14, 401-6	3.3	11
184	Catecholamine metabolomic and secretory phenotypes in pheochromocytoma. <i>Endocrine-Related Cancer</i> , <b>2011</b> , 18, 97-111	5.7	127
183	Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 411-20	5.5	225

182	Hypertension in pheochromocytoma: characteristics and treatment. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2011</b> , 40, 295-311, vii	5.5	101
181	Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 2779-85	5.6	107
180	Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 375-84	5.6	65
179	Drugs and Pheochromocytoma Don't Be Fooled by Every Elevated Metanephrine. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 2268-2270	59.2	67
178	Increased uptake of [ <sup>123</sup> I]meta-iodobenzylguanidine, [ <sup>18</sup> F]fluorodopamine, and [ <sup>3</sup> H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. <i>Endocrine-Related Cancer</i> , <b>2011</b> , 18, 143-57	5.7	28
177	Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4137-42	2.2	136
176	Bilateral adrenal medullary hyperplasia associated with an SDHB mutation. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, e200-2	2.2	29
175	An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 880-92	15.9	52
174	Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy. <i>PLoS ONE</i> , <b>2011</b> , 6, e14678	3.7	29
173	Drugs and pheochromocytoma--don't be fooled by every elevated metanephrine. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 2268-70	59.2	14
172	New imaging approaches to phaeochromocytomas and paragangliomas. <i>Clinical Endocrinology</i> , <b>2010</b> , 72, 137-45	3.4	104
171	Response to Letter to the Editor by Dullaart et al.. <i>Clinical Endocrinology</i> , <b>2010</b> , 72, 569-570	3.4	
170	Minimal changes in environmental temperature result in a significant increase in energy expenditure and changes in the hormonal homeostasis in healthy adults. <i>European Journal of Endocrinology</i> , <b>2010</b> , 163, 863-72	6.5	61
169	Succinate dehydrogenase gene mutations are strongly associated with paraganglioma of the organ of Zuckerkandl. <i>Endocrine-Related Cancer</i> , <b>2010</b> , 17, 581-8	5.7	26
168	Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. <i>Hypertension Research</i> , <b>2010</b> , 33, 454-9	4.7	27
167	The use of functional imaging in a patient with head and neck paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 481-2	5.6	17
166	Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 238-45	5.6	21
165	SDH-related pheochromocytoma and paraganglioma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 24, 415-24	6.5	61

164	G(s)alpha deficiency in adipose tissue leads to a lean phenotype with divergent effects on cold tolerance and diet-induced thermogenesis. <i>Cell Metabolism</i> , <b>2010</b> , 11, 320-30	24.6	33
163	In vivo micro-CT imaging of liver lesions in small animal models. <i>Methods</i> , <b>2010</b> , 50, 20-5	4.6	33
162	Functional and oncologic outcomes of partial adrenalectomy for pheochromocytoma in patients with von Hippel-Lindau syndrome after at least 5 years of followup. <i>Journal of Urology</i> , <b>2010</b> , 184, 1855-9	3.5	58
161	Pheochromocytoma and paraganglioma. <i>Progress in Brain Research</i> , <b>2010</b> , 182, 343-73	2.9	49
160	Partial adrenalectomy: underused first line therapy for small adrenal tumors. <i>Journal of Urology</i> , <b>2010</b> , 184, 18-25	2.5	69
159	Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload. <i>Circulation Research</i> , <b>2010</b> , 106, 193-202	15.7	156
158	The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. <i>Pancreas</i> , <b>2010</b> , 39, 775-83	2.6	371
157	Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla. <i>Cell and Tissue Research</i> , <b>2010</b> , 340, 607-12	4.2	12
156	Exercise-induced nausea and vomiting: another sign and symptom of pheochromocytoma and paraganglioma. <i>Endocrine</i> , <b>2010</b> , 37, 403-7	4	13
155	Genetic testing for pheochromocytoma. <i>Current Hypertension Reports</i> , <b>2010</b> , 12, 456-64	4.7	46
154	Carboxypeptidase E: elevated expression correlated with tumor growth and metastasis in pheochromocytomas and other cancers. <i>Cellular and Molecular Neurobiology</i> , <b>2010</b> , 30, 1377-81	4.6	31
153	Metastatic paraganglioma. <i>Seminars in Oncology</i> , <b>2010</b> , 37, 627-37	5.5	70
152	Development and validation of a comprehensive mutation and deletion detection assay for SDHB, SDHC, and SDHD. <i>Clinical Biochemistry</i> , <b>2010</b> , 43, 700-4	3.5	5
151	Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. <i>Hormones</i> , <b>2009</b> , 8, 111-6	3.1	33
150	Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 2952-7	5.6	19
149	Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 4757-67	5.6	305
148	Mediastinal paragangliomas: association with mutations in the succinate dehydrogenase genes and aggressive behavior. <i>Endocrine-Related Cancer</i> , <b>2009</b> , 16, 291-9	5.7	34
147	Clinical aspects of SDHx-related pheochromocytoma and paraganglioma. <i>Endocrine-Related Cancer</i> , <b>2009</b> , 16, 391-400	5.7	101



146	Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. <i>Journal of Nuclear Medicine</i> , <b>2009</b> , 50, 1448-54	8.9	113
145	Noninvasive monitoring of a murine model of metastatic pheochromocytoma: a comparison of contrast-enhanced microCT and nonenhanced MRI. <i>Journal of Magnetic Resonance Imaging</i> , <b>2009</b> , 29, 685-91	5.6	32
144	Update on pediatric pheochromocytoma. <i>Pediatric Nephrology</i> , <b>2009</b> , 24, 943-50	3.2	81
143	Malignant paraganglioma associated with succinate dehydrogenase subunit B in an 8-year-old child: the age of first screening?. <i>Pediatric Nephrology</i> , <b>2009</b> , 24, 1239-42	3.2	14
142	Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. <i>Clinical and Experimental Metastasis</i> , <b>2009</b> , 26, 239-50	4.7	50
141	Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic pheochromocytoma (PHEO). <i>Clinical Endocrinology</i> , <b>2009</b> , 71, 11-7	3.4	70
140	Central nervous system imprinting of the G protein G(s)alpha and its role in metabolic regulation. <i>Cell Metabolism</i> , <b>2009</b> , 9, 548-55	24.6	104
139	A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. <i>American Journal of Pathology</i> , <b>2009</b> , 174, 2051-60	5.8	17
138	An immunohistochemical procedure to detect patients with paraganglioma and pheochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. <i>Lancet Oncology</i> , <b>2009</b> , 10, 764-71	21.7	405
137	Radiofrequency ablation of metastatic pheochromocytoma. <i>Journal of Vascular and Interventional Radiology</i> , <b>2009</b> , 20, 1483-90	2.4	41
136	Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling. <i>Annals of Surgery</i> , <b>2009</b> , 250, 983-90	7.8	16
135	Brief communication: radiographic contrast infusion and catecholamine release in patients with pheochromocytoma. <i>Annals of Internal Medicine</i> , <b>2009</b> , 150, 27-32	8	27
134	Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. <i>European Journal of Human Genetics</i> , <b>2008</b> , 16, 79-88	5.3	377
133	Mutations associated with succinate dehydrogenase D-related malignant paragangliomas. <i>Clinical Endocrinology</i> , <b>2008</b> , 68, 561-6	3.4	39
132	A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. <i>Nuclear Medicine and Biology</i> , <b>2008</b> , 35 Suppl 1, S27-34	2.1	54
131	Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2008</b> , 295, E1223-33	6	47
130	Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. <i>Endocrine-Related Cancer</i> , <b>2008</b> , 15, 311-23	5.7	54
129	Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature. <i>European Journal of Endocrinology</i> , <b>2008</b> , 158, 423-9	6.5	69

128	Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. <i>Journal of Nuclear Medicine</i> , <b>2008</b> , 49, 1613-9	8.9	124
127	Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2008</b> , 93, 4826-32	5.6	86
126	Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma. <i>Endocrine</i> , <b>2008</b> , 34, 96-100	4	12
125	Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells. <i>Molecular Carcinogenesis</i> , <b>2008</b> , 47, 245-51	5	14
124	Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. <i>Cancer</i> , <b>2008</b> , 113, 2020-8	6.4	188
123	Unexplained symptomatic paroxysmal hypertension in pseudopheochromocytoma: a stress response disorder?. <i>Annals of the New York Academy of Sciences</i> , <b>2008</b> , 1148, 469-78	6.5	11
122	Pheochromocytoma: an endocrine stress mimicking disorder. <i>Annals of the New York Academy of Sciences</i> , <b>2008</b> , 1148, 462-8	6.5	14
121	Pheochromocytoma. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2008</b> , 5, E1		6
120	Clinical review: Current treatment of malignant pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 1217-25	5.6	147
119	Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. <i>Drug Safety</i> , <b>2007</b> , 30, 1031-62	5.1	85
118	Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2007</b> , 3, 92-102		467
117	An assessment of biochemical tests for the diagnosis of pheochromocytoma. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2007</b> , 3, 744-5		16
116	Cardiac sympathetic denervation preceding motor signs in Parkinson disease. <i>Clinical Autonomic Research</i> , <b>2007</b> , 17, 118-21	4.3	77
115	Preoperative management of the pheochromocytoma patient. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 4069-79	5.6	393
114	Adenoviral gene transfer in bovine adrenomedullary and murine pheochromocytoma cells: potential clinical and therapeutic relevance. <i>Endocrinology</i> , <b>2007</b> , 148, 3900-7	4.8	5
113	Elevated inflammation markers in pheochromocytoma compared to other forms of hypertension. <i>NeuroImmunoModulation</i> , <b>2007</b> , 14, 57-64	2.5	30
112	Mitochondrial localization of human recombinant adenovirus: from evolution to gene therapy. <i>NeuroImmunoModulation</i> , <b>2007</b> , 14, 221-3	2.5	3
111	The incidentally discovered adrenal mass. <i>New England Journal of Medicine</i> , <b>2007</b> , 356, 2005	59.2	15

110	Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 779-86	5.6	228
109	Brown fat imaging with (18)F-6-fluorodopamine PET/CT, (18)F-FDG PET/CT, and (123)I-MIBG SPECT: a study of patients being evaluated for pheochromocytoma. <i>Journal of Nuclear Medicine</i> , <b>2007</b> , 48, 1077-83	8.9	80
108	The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. <i>Journal of Nuclear Medicine</i> , <b>2007</b> , 48, 1599-606	8.9	88
107	Usefulness of standardized uptake values for distinguishing adrenal glands with pheochromocytoma from normal adrenal glands by use of 6-18F-fluorodopamine PET. <i>Journal of Nuclear Medicine</i> , <b>2007</b> , 48, 1940-4	8.9	21
106	Is supine rest necessary before blood sampling for plasma metanephrines?. <i>Clinical Chemistry</i> , <b>2007</b> , 53, 352-4	5.5	96
105	Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2262-9	2.2	272
104	Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. <i>Endocrine-Related Cancer</i> , <b>2007</b> , 14, 463-71	5.7	12
103	The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. <i>European Journal of Endocrinology</i> , <b>2007</b> , 156, 483-7	6.5	70
102	Neuropeptide Y expression in pheochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome. <i>Journal of Endocrinology</i> , <b>2007</b> , 193, 225-33	4.7	11
101	Familial pheochromocytomas and paragangliomas associated with mutations of the succinate dehydrogenase genes. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2007</b> , 2, 399-406	4.1	1
100	Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. <i>Journal of Hypertension</i> , <b>2007</b> , 25, 2286-95	1.9	32
99	ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice. <i>Cell Cycle</i> , <b>2007</b> , 6, 1946-50	4.7	15
98	The optimal imaging of adrenal tumours: a comparison of different methods. <i>Endocrine-Related Cancer</i> , <b>2007</b> , 14, 587-99	5.7	176
97	Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. <i>BMC Cancer</i> , <b>2006</b> , 6, 131	4.8	21
96	MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice. <i>International Journal of Cancer</i> , <b>2006</b> , 119, 2236-41	7.5	26
95	High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 4505-9	5.6	255
94	Emergencies caused by pheochromocytoma, neuroblastoma, or ganglioneuroma. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2006</b> , 35, 699-724, viii	5.5	47
93	Utility of plasma free metanephrines in diagnosis of factitious pheochromocytoma. <i>Endocrine Practice</i> , <b>2006</b> , 12, 568-71	3.2	6

92	Uncommon Endocrine Tumors in Children and Adolescents <b>2006</b> , 775-797		1
91	Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [(123)I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites. <i>Nuclear Medicine Communications</i> , <b>2006</b> , 27, 31-6	1.6	75
90	Characteristics of blood pressure in pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 1073, 86-93	6.5	12
89	Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 1073, 241-52	6.5	21
88	Animal models of pheochromocytoma including NIH initial experience. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 1073, 300-5	6.5	6
87	Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus?. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 1073, 332-47	6.5	90
86	Current trends in functional imaging of pheochromocytomas and paragangliomas. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 1073, 374-82	6.5	41
85	Anatomical and functional imaging of tumors in animal models: focus on pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 1073, 392-404	6.5	10
84	Gene expression profiling of benign and malignant pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , <b>2006</b> , 1073, 541-56	6.5	50
83	Phaeochromocytoma. <i>Lancet, The</i> , <b>2005</b> , 366, 665-75	4.0	1229
82	Combined corticotropin-releasing hormone and glucocorticoid deficiency does not enhance counterregulatory responses after recurrent hypoglycemia in mice. <i>Metabolism: Clinical and Experimental</i> , <b>2005</b> , 54, 1259-65	12.7	6
81	New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. <i>Trends in Endocrinology and Metabolism</i> , <b>2005</b> , 16, 66-72	8.8	55
80	Leptin concentrations in the abdominal subcutaneous adipose tissue of patients with anorexia nervosa assessed by in vivo microdialysis. <i>Regulatory Peptides</i> , <b>2005</b> , 128, 63-8		22
79	Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. <i>Journal of Hypertension</i> , <b>2005</b> , 23, 2033-9	1.9	35
78	Plasma metanephrines in renal failure. <i>Kidney International</i> , <b>2005</b> , 67, 668-77	9.9	57
77	Downregulation of metastasis suppressor genes in malignant pheochromocytoma. <i>International Journal of Cancer</i> , <b>2005</b> , 114, 139-43	7.5	87
76	Expression of the noradrenaline transporter and phenylethanolamine N-methyltransferase in normal human adrenal gland and phaeochromocytoma. <i>Cell and Tissue Research</i> , <b>2005</b> , 322, 443-53	4.2	21
75	Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 735-44	5.5	145

74	Differential expression of erythropoietin and its receptor in von hippel-lindau-associated and multiple endocrine neoplasia type 2-associated pheochromocytomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 3747-51	5.6	22
73	Cushing $\beta$ syndrome due to ectopic corticotropin secretion: twenty yearsPexperience at the National Institutes of Health. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 4955-62	5.6	474
72	Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 2068-75	5.6	178
71	Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. <i>European Journal of Endocrinology</i> , <b>2005</b> , 153, 551-63	6.5	51
70	A new concept of unopposed beta-adrenergic overstimulation in a patient with pheochromocytoma. <i>Annals of Internal Medicine</i> , <b>2005</b> , 142, 1026-8	8	6
69	Diagnostic imaging of pheochromocytoma. <i>Frontiers of Hormone Research</i> , <b>2004</b> , 31, 107-20	3.5	11
68	Biochemical diagnosis of pheochromocytoma. <i>Frontiers of Hormone Research</i> , <b>2004</b> , 31, 76-106	3.5	38
67	Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 479-91	5.6	251
66	The role of [(18F)]fluorodeoxyglucose positron emission tomography and [(111)In]-diethylenetriaminepentaacetate-D-Phe-pentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing $\beta$ syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 2214-21	5.6	115
65	Malignant pheochromocytoma: current status and initiatives for future progress. <i>Endocrine-Related Cancer</i> , <b>2004</b> , 11, 423-36	5.7	262
64	Cardiac uptake-1 inhibition by high circulating norepinephrine levels in patients with pheochromocytoma. <i>Hypertension</i> , <b>2004</b> , 43, 1227-32	8.5	15
63	Diagnosis and localization of pheochromocytoma. <i>Hypertension</i> , <b>2004</b> , 43, 907-10	8.5	34
62	Functional imaging of endocrine tumors: role of positron emission tomography. <i>Endocrine Reviews</i> , <b>2004</b> , 25, 568-80	27.2	130
61	Anatomical and functional imaging of metastatic pheochromocytoma. <i>Annals of the New York Academy of Sciences</i> , <b>2004</b> , 1018, 495-504	6.5	40
60	Laparoscopic management of extra-adrenal pheochromocytoma. <i>Journal of Urology</i> , <b>2004</b> , 171, 72-6	2.5	43
59	Endocrine withdrawal syndromes. <i>Endocrine Reviews</i> , <b>2003</b> , 24, 523-38	27.2	109
58	Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 2656-66	5.6	370
57	Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 4083-7	5.6	207

56	Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-[18F]-fluorodopamine positron emission tomography. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 637-41	5.6	55
55	Loss of meal-induced decrease in plasma ghrelin levels in patients with anorexia nervosa. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 1678-82	5.6	130
54	Effects of hypo- and hyperthyroidism on noradrenergic activity and glycerol concentrations in human subcutaneous abdominal adipose tissue assessed with microdialysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 5605-8	5.6	39
53	Hypotension in a woman with a metastatic dopamine-secreting carotid body tumor. <i>Endocrine Practice</i> , <b>2003</b> , 9, 310-4	3.2	18
52	Pheochromocytoma as an endocrine emergency. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2003</b> , 4, 121-8	10.5	65
51	Diagnostic Localization of Malignant Bladder Pheochromocytoma Using 6-[ 18 F]Fluorodopamine Positron Emission Tomography. <i>Journal of Urology</i> , <b>2003</b> , 169, 274-275	2.5	19
50	Choice of biochemical test for diagnosis of pheochromocytoma: validation of plasma metanephrines. <i>Current Hypertension Reports</i> , <b>2002</b> , 4, 250-5	4.7	24
49	Local sympathetic function in human skeletal muscle and adipose tissue assessed by microdialysis. <i>Clinical Autonomic Research</i> , <b>2002</b> , 12, 13-9	4.3	9
48	Somatic VHL gene deletion and point mutation in MEN 2A-associated pheochromocytoma. <i>Oncogene</i> , <b>2002</b> , 21, 479-82	9.2	29
47	New insights into the genetics of familial chromaffin cell tumors. <i>Annals of the New York Academy of Sciences</i> , <b>2002</b> , 970, 11-28	6.5	48
46	New advances in the biochemical diagnosis of pheochromocytoma: moving beyond catecholamines. <i>Annals of the New York Academy of Sciences</i> , <b>2002</b> , 970, 29-40	6.5	59
45	Genomic medicine: exploring the basis of a new approach to endocrine hypertension. <i>Annals of the New York Academy of Sciences</i> , <b>2002</b> , 970, 177-92	6.5	3
44	Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. <i>Endocrine Pathology</i> , <b>2002</b> , 13, 17-27	4.2	58
43	Survivin: a novel neuroendocrine marker for pheochromocytoma. <i>European Journal of Endocrinology</i> , <b>2002</b> , 146, 381-8	6.5	28
42	Utility of plasma free metanephrines for detecting childhood pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 1955-60	5.6	78
41	The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2002</b> , 87, 5367-84	5.6	143
40	Biochemical diagnosis of pheochromocytoma: which test is best?. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 287, 1427-34	27.4	792
39	Management of Malignant Pheochromocytoma <b>2002</b> , 12, 291-299		6



38	Chronic hypercortisolemia inhibits dopamine synthesis and turnover in the nucleus accumbens: an in vivo microdialysis study. <i>Neuroendocrinology</i> , <b>2002</b> , 76, 148-57	5.6	36
37	Diagnostic localization of pheochromocytoma: the coming of age of positron emission tomography. <i>Annals of the New York Academy of Sciences</i> , <b>2002</b> , 970, 170-6	6.5	49
36	Catecholamines in the Brain and Responses to Environmental Challenges <b>2001</b> , 45-60		
35	Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. <i>Annals of Internal Medicine</i> , <b>2001</b> , 134, 315-29	8	402
34	Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2001</b> , 2, 297-311	10.5	119
33	Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma. <i>Oncogene</i> , <b>2001</b> , 20, 7809-11	9.2	37
32	Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 1999-2008	5.6	224
31	6-[ <sup>18</sup> F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. <i>Hypertension</i> , <b>2001</b> , 38, 6-8	8.5	183
30	Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 648-9	9.7	73
29	A "pheo" lurks: novel approaches for locating occult pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 3641-6	5.6	46
28	The role of dopamine in methylene blue-mediated inhibition of estradiol benzoate-induced anterior pituitary hyperplasia in rats. <i>Neuroscience Letters</i> , <b>2001</b> , 304, 194-8	3.3	4
27	INCREASED PLASMA NOREPINEPHRINE CONCENTRATION IN CATS WITH INTERSTITIAL CYSTITIS. <i>Journal of Urology</i> , <b>2001</b> , 165, 2051-2054	2.5	56
26	Increased plasma norepinephrine concentration in cats with interstitial cystitis. <i>Journal of Urology</i> , <b>2001</b> , 165, 2051-4	2.5	14
25	CRH deficiency impairs but does not block pituitary-adrenal responses to diverse stressors. <i>Neuroendocrinology</i> , <b>2000</b> , 71, 79-87	5.6	64
24	Impaired basal and restraint-induced epinephrine secretion in corticotropin-releasing hormone-deficient mice. <i>Endocrinology</i> , <b>2000</b> , 141, 1142-50	4.8	70
23	Paternal versus maternal transmission of a stimulatory G-protein alpha subunit knockout produces opposite effects on energy metabolism. <i>Journal of Clinical Investigation</i> , <b>2000</b> , 105, 615-23	15.9	121
22	How do levels of (endogenous) glucocorticoids, interleukin-10 and interleukin-12 relate to multiple sclerosis relapse before, during and after pregnancy?. <i>Clinical Endocrinology</i> , <b>1999</b> , 50, 818-9	3.4	5
21	Stressor-specific activation of catecholaminergic systems: implications for stress-related hypothalamic-pituitary-adrenocortical responses. <i>Advances in Pharmacology</i> , <b>1998</b> , 42, 561-4	5.7	20

20	Heterogeneous neurochemical responses to different stressors: a test of Selye's doctrine of nonspecificity. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>1998</b> , 275, R1247-55	3.2	85
19	Regulation of Peripheral Catecholamine Responses to Acute Stress in Young Adult and Aged F-344 Rats. <i>Stress</i> , <b>1997</b> , 2, 113-122	3	15
18	Hyperinsulinemia and sympathoadrenal system activity in the rat. <i>Annals of the New York Academy of Sciences</i> , <b>1997</b> , 827, 118-34	6.5	11
17	Chronic blockade of nitric oxide synthesis elevates plasma levels of catecholamines and their metabolites at rest and during stress in rats. <i>Neurochemical Research</i> , <b>1997</b> , 22, 995-1001	4.6	20
16	Triiodothyronine attenuates estradiol-induced increases in dopamine D-2 receptor number in rat anterior pituitary. <i>Brain Research</i> , <b>1996</b> , 712, 148-52	3.7	10
15	Interrelations between sympathoadrenal system and hypothalamo-pituitary-adrenocortical/thyroid systems in rats exposed to cold stress. <i>Journal of Neuroendocrinology</i> , <b>1996</b> , 8, 533-41	3.8	53
14	Brainstem hemisection decreases corticotropin-releasing hormone mRNA in the paraventricular nucleus but not in the central amygdaloid nucleus. <i>Journal of Neuroendocrinology</i> , <b>1996</b> , 8, 543-51	3.8	30
13	Disprocynium24, a novel inhibitor of the extraneuronal monoamine transporter, has potent effects on the inactivation of circulating noradrenaline and adrenaline in conscious rat. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>1996</b> , 354, 287-94	3.4	28
12	Stress-induced norepinephrine release in the hypothalamic paraventricular nucleus and pituitary-adrenocortical and sympathoadrenal activity: in vivo microdialysis studies. <i>Frontiers in Neuroendocrinology</i> , <b>1995</b> , 16, 89-150	8.9	299
11	Effects of immobilization on in vivo release of norepinephrine in the bed nucleus of the stria terminalis in conscious rats. <i>Brain Research</i> , <b>1995</b> , 688, 242-6	3.7	89
10	Effects of hypercortisolemia or hyperinsulinemia on neurochemical indices of catecholamine release and synthesis in conscious rats. <i>Journal of the Autonomic Nervous System</i> , <b>1995</b> , 54, 104-12		2
9	Effects of various stressors on in vivo norepinephrine release in the hypothalamic paraventricular nucleus and on the pituitary-adrenocortical axis. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 771, 115-30	6.5	132
8	Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism?. <i>Clinical Science</i> , <b>1995</b> , 88, 533-42	6.5	84
7	The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. <i>Journal of the Autonomic Nervous System</i> , <b>1994</b> , 50, 93-107		25
6	Glycine stimulates striatal dopamine release in conscious rats. <i>British Journal of Pharmacology</i> , <b>1993</b> , 110, 50-3	8.6	31
5	Effects of single or repeated immobilization on release of norepinephrine and its metabolites in the central nucleus of the amygdala in conscious rats. <i>Neuroendocrinology</i> , <b>1993</b> , 57, 626-33	5.6	62
4	Stress-induced norepinephrine release in the paraventricular nucleus of rats with brainstem hemisections: a microdialysis study. <i>Neuroendocrinology</i> , <b>1993</b> , 58, 196-201	5.6	57
3	Role of CRH in glucopenia-induced adrenomedullary activation in rats. <i>Journal of Neuroendocrinology</i> , <b>1993</b> , 5, 475-86	3.8	24

- 2 Noradrenergic activation in the paraventricular nucleus during acute and chronic immobilization stress in rats: an in vivo microdialysis study. *Brain Research*, **1992**, 589, 91-6 3-7 104
- 1 Sympathoneural and skeletal muscle contributions to plasma dopa responses in pithed rats. *Journal of the Autonomic Nervous System*, **1991**, 35, 169-74 3